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hat Promise
oes PCSK9 Hold?*
ohn J. P. Kastelein, MD, PHD,
igrid W. Fouchier, MSC,
oep C. Defesche, PHD
msterdam, the Netherlands
he cholesterol hypothesis has been with us for almost a
entury. Nevertheless, only in the last three decades, after
he discovery of the low-density lipoprotein (LDL) and
evalonate pathways by Brown and Goldstein, lipoprotein
etabolism has become the subject of intensive research
1,2). The discovery that mutations in the LDL receptor
ene are the cause of familial hypercholesterolemia (FH)
as, among other findings, enabled us to discern FH from
ther types of hypercholesterolemia, either inherited or
cquired. The subsequent elucidation of the mevalonate
athway, with hydroxyl-methylglutaryl coenzyme A reduc-
ase as the rate-limiting enzyme in cholesterol synthesis, has
eralded the development of inhibitors of this enzyme, the
o-called statins (3). Statins are the drugs of choice in the
reatment of elevated cholesterol levels and in the preven-
ion of cardiovascular disease and will remain the backbone
f any treatment regimen in this area for many years to
See page 1611
ome. In 1987, it became evident that there was a second
enetic cause for inherited hypercholesterolemia. Patients
ith this disorder carry LDL particles that are not able to
ind to the LDL receptor because of mutations in the gene
hat codes for apolipoproteinB 100 (apoB), the structural
rotein component of LDL that interacts with this receptor
4,5). This genetically distinct cause of inherited hypercho-
esterolemia was coined familial defective apolipoprotein B,
r FDB. Although from a therapeutic perspective the
iscovery of FDB did not lead to new insights, it did provide
dditional focus on the atherogenic potential of apoB. This
nsight has contributed to the notion that the ratio apoB/
poA1 has emerged as the single best predictor for cardio-
ascular disease, as firmly established by the Interheart
tudy recently (6).
Until very recently, it was fair to say that in most
opulations approximately 65% of the cases of inherited
ypercholesterolemia could be explained by mutations in
he LDL receptor gene and in 10% by mutations in the
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.n
From the Department of Vascular Medicine, Academic Medical Center at the
niversity of Amsterdam, Amsterdam, the Netherlands.poB gene. The underlying genetic cause of the remaining
5% of individuals suffering from inherited hypercholester-
lemia now appears to be partly resolved with the finding
hat proprotein convertase subtilisin/kexin 9, or PCSK9,
ikely plays an important role in cholesterol metabolism.
The question now is: does PCSK9 hold the same promise
s apoB and the LDL receptor 15 and 30 years ago? Will
he elucidation of the role of PCSK9 equally contribute to
he improvement of diagnosis, risk estimation, and the
evelopment of new therapeutic targets in cardiovascular
isease prevention? Unfortunately, the situation surround-
ng PCSK9 is, at minimal, conflicting and confusing. Let us
eview how this situation has arisen.
In 1999, a French group identified a locus on chromo-
ome 1 that was linked to inherited hypercholesterolemia
7) and in May 2003, the same group pinpointed PCSK9 to
hromosome 1p32 (8). PCSK9 is a protease whose precise
unction is not fully understood. It probably can activate or
eactivate other proteins by proteolytic cleavage. The
rench group reported two mutations in the coding region
f the PCSK9 gene that segregated with a hypercholester-
lemic phenotype, in which the LDL receptor and the apoB
enes were excluded as the cause of inherited hypercholes-
erolemia. These researchers also introduced the term
utosomal-dominant hypercholesterolemia (ADH) to refer
o the three genetically distinct forms of hypercholesterol-
mia that are inherited in an autosomal dominant fashion,
ut that are clinically undistinguishable: FH caused by
utations in the LDL-receptor gene, FDB caused by
utations in the apoB-gene, and FH3, caused by a, up to
hat time, unknown genes. Since the time that PCSK9 was
eported as the putative third locus involved in ADH,
everal studies have been published, including the study by
hen et al. (9) in this issue of the Journal. These colleagues
nvestigated the role of PCSK9 and the molecular variation
n this gene in the metabolism of LDL-cholesterol (8,10–
3). Regretfully, these recent studies have not been able to
nequivocally confirm PCSK9 as the third gene causing
DH, and the reported results vary from definitely caus-
tive, e.g., Timms et al. (10) and Leren (11) to definitely not
ausative (14). The essential difference between the first
eport by Abifadel et al. (8) and the investigations that
ollowed, lies in the fact that Abifadel et al. (8) identified a
hromosomal segment on chromosome 1 that harbored the
CSK9 gene, plus 42 other known genes, whereas other
esearchers were focused directly onto the PCSK9 gene. The
tudy by Abifadel et al. (8) does not rule out the possibility
hat the missense mutations that were identified in PCSK9
re in fact not the cause of ADH but that they might be in
inkage disequilibrium with other genetic variants on the
ame chromosomal segment of 5.2 megabases. Such reason-
ble doubt is strengthened by the fact that functional assays
f the effects of these mutations on PCSK9 function have
ot been performed so far. Nevertheless, PCSK9 has
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May 17, 2005:1620–1 Editorial Commentmerged as a candidate for the third ADH gene because a
ole for PCSK9 in cholesterol metabolism is evident.
Recent gene expression data obtained from hepatic tissue of
holesterol-fed mice have shown that PCSK9 expression is
ignificantly down-regulated by dietary cholesterol (15). In
greement with these findings, up-regulation becomes evident
hen human liver cells are cholesterol depleted (13). Also,
verexpression of PCSK9 in mice results in a similar phenotype
s in mice lacking the LDL receptor (15). This severely
levated cholesterol phenotype is supposed to be the result of
apid degradation of the LDL receptor protein because over-
xpression of PCSK9 caused a 72% decrease in LDL receptor
rotein, whereas LDL receptor mRNA levels were in the
ormal range (16,17). This notion is further strengthened by
he observation that overexpression of PCSK9 in LDL
eceptor-deficient mice does not result in additional elevation
f cholesterol levels (15). Despite these solid data in animals,
he mechanism by which genetic variants in PCSK9 affect
DL cholesterol levels in humans is still poorly understood.
he obvious conflicting situation has now arisen insofar that
igh PCSK9 activity levels in mice result in elevated cholesterol
evels, whereas in contrast in humans, reduced PCSK9 activity
eads to an elevated cholesterol phenotype.
Therefore, novel attempts, such as the study by Chen et
l. (9) in this issue of the Journal, to further clarify the role
f PCSK9 in cholesterol metabolism have been eagerly
waited. In this study, several novel and known genetic
ariants in the PCSK9 gene were assessed. One variant,
670G, a substitution of glutamic acid by glycin at amino
cid position 670, indeed explained as much as 3.5% of the
ariation in LDL cholesterol levels, confirming a role for
CSK9. Nevertheless, a gene dosage effect, which might
ave indicated a direct functional influence on enzyme
ctivity in human lipoprotein metabolism, was not observed.
ipoprotein levels associated with wild type (EE) and the
eterozygous (EG) form were essentially similar, and only
he homozygous (GG) form was associated with elevated
DL cholesterol levels. However, these findings might have
een the result of reduced power because of limited sample
ize. In view of the modest elevation of LDL cholesterol by
he homozygous GG form, the clinical implications of these
ndings seem to be limited. The risk of coronary athero-
clerosis only showed an upward trend in GG carriers and
he response to cholesterol lowering treatment with fluva-
tatin was not influenced by presence or absence of the G
ariant. Therefore, the currently gathered knowledge does
ot seem to provide the final answer to the questions that
ave arisen since the implication of PCSK9 in hereditary
efects in human lipoprotein metabolism. The study by
hen et al. (9) should be replicated in other populations,
deally with a large enough sample size to generate the
efinitive data. So far, a significant impact on cardiovascularisk or treatment of cardiovascular disease has not been part
f the PCSK9 story.
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